Mylan Has Now Received All Antitrust Regulatory Clearances to Acquire Meda



, and



July 27, 2016

/PRNewswire/ --

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in,



Hong Kong






New Zealand


South Africa

, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law (including the Takeover Rules), Dutch law,

United Kingdom

law, Danish law, Irish law and U.S. law.

Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Federal Trade Commission ("FTC") has cleared Mylan's proposed transaction to acquire Meda Aktiebolag (publ.) subject to Mylan's divestiture of certain products not significant to Mylan's earnings following the consummation of its recommended public offer to the shareholders of Meda to tender all their shares in Meda to Mylan (the "Offer").

The FTC clearance represents the final regulatory clearance required to complete the Offer and Mylan has now received all antitrust regulatory clearances required to acquire Meda. As a result, completion of the Offer is no longer conditional upon receipt of further regulatory or government clearances.

The acceptance period for the Offer runs up to and including

July 29, 2016

. Mylan reserves the right to extend the acceptance period. Mylan also reserves the right to postpone the settlement date. Mylan will announce any extension of the acceptance period and/or postponement of the settlement date by a press release in accordance with applicable laws and regulations.

An offer document regarding the Offer (the "Offer Document") and the prospectus issued in connection with the Offer (the "EU Prospectus") were each made public on

June 16, 2016

and, on

July 21, 2016

, Mylan published supplements to each of the Offer Document and the EU Prospectus (the "Supplements"). Mylan has also filed a Registration Statement on Form S-4 (the "Registration Statement") which was declared effective on

June 16, 2016


Related Videos
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg -
Image credit: |
Medical team -- Image credit: Flamingo Images |
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin -
© 2024 MJH Life Sciences

All rights reserved.